PKP2

Across TCGA pan-cancer cohorts, PKP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PKP2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PKP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PKP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, LUAD, and COAD are the cancer types where PKP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.627	0.370	.003	61	view →
LUAD	OS	Median	II,III,IV	0.427	0.807	.013	20	view →
COAD	DFS	Tertile	All	1.000	0.884	.043	12	view →
HNSC	OS	Quartile	All	0.588	0.828	.025	6	view →
CCRCC	OS	Median	All	0.969	0.836	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PKP2–PDAC (OS)

Open the PDAC breakdown →